Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | KCNN3 | Q9UGI6 | 2/20 | 0.32 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.31 |
| ▸ | TDO2 | P48775 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13595100 | 0.78 | MAPT (0.44) | MAPTRAB9ANPC1ATMSMN1; SMN2 | |
| SCHEMBL4413940 | 0.77 | ADORA2A (0.37) | MAPTNPC1L3MBTL1KDM4EALDH1A1 | |
| SCHEMBL4406314 | 0.76 | — | — | |
| SCHEMBL4412489 | 0.75 | — | — | |
| SCHEMBL4404585 | 0.75 | — | — | |
| SCHEMBL4404584 | 0.71 | HSD17B10 (0.45) | MAPTATML3MBTL1KDM4EALDH1A1 | |
| SCHEMBL12918501 | 0.66 | MAPT (0.53) | MAPTRAB9ANPC1ATMSMN1; SMN2 | |
| SCHEMBL4408162 | 0.64 | GBA1 (0.37) | HDAC4 | |
| SCHEMBL9863892 | 0.63 | ACHE (0.30) | — | |
| SCHEMBL21143612 | 0.63 | RAB9A (0.50) | MAPTRAB9ANPC1ATMSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090325889-A1 | HEPATITIS C SERINE PROTEASE INHIBITORS AND USES THEREFOR | CAMPBELL DAVID ALAN | 2009-12-31 | — | — | US | claimed |
| EP-1915382-A2 | HEPATITIS C SERINE PROTEASE INHIBITORS AND USES THEREFOR | Phenomix Corporation (US) | 2008-04-30 | — | — | EP | claimed |
| WO-2007016476-A2 | HEPATITIS C SERINE PROTEASE INHIBITORS AND USES THEREFOR | PHENOMIX CORPORATION (US) | 2007-02-08 | — | — | WO | claimed |
| US-20090325889-A1 | HEPATITIS C SERINE PROTEASE INHIBITORS AND USES THEREFOR | CAMPBELL DAVID ALAN | 2009-12-31 | — | — | US | disclosed |
| EP-1915382-A2 | HEPATITIS C SERINE PROTEASE INHIBITORS AND USES THEREFOR | Phenomix Corporation (US) | 2008-04-30 | — | — | EP | disclosed |
| WO-2007016476-A2 | HEPATITIS C SERINE PROTEASE INHIBITORS AND USES THEREFOR | PHENOMIX CORPORATION (US) | 2007-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090325889-A1 | HEPATITIS C SERINE PROTEASE INHIBITORS AND USES THEREFOR | PREP, HPN, PRSS1 | MAPT 4214/4885RAB9A 3965/4885NPC1 788/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.